Compare BIO-TECHNE Corp (TECH) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Vanguard S&P 500 Growth Index Fund ETF trades at $83.75. The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none. Which is the better fit depends on your goals.
| TECH | VOOG | |
|---|---|---|
Market Cap | $11.34B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $72.48 | $85.69 |
52-Week Low | $43.31 | $65.32 |
Enterprise Value | $11.36B | — |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
VOOG trades at $84.08, down 0.5% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on S&P 500 growth stocks, offering exposure to large-cap leaders with a low expense ratio of 0.07% (Vanguard, 2026). Recent news highlights strong long-term performance, including over 400% total returns in the past decade (The Motley Fool, 2026-09-07).
Outlook remains positive for growth-oriented investors, supported by institutional buying and media optimism. Key risks include tech sector concentration and market volatility. Analysts favor VOOG for its cost efficiency and historical outperformance, though valuation sensitivity persists amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
